Regulatory T cells (Tregs ... The staggering diversity of T-cell antigen receptor recognition derives from an ingenious genetic ploy: small DNA snippets in thymocytes—nascent T cells undergoing ...

Celiac disease is also a good candidate for regulatory T-cell therapy because in more than 90% of patients it is caused by a genetic variant called HLA-DQ2.5, Muller added. “Almost all the ...

RegCell, Inc., a biotechnology company developing first-in-class therapies for autoimmune diseases and transplantation with its epigenetic reprogramming platform leveraging the natural biology of ...

Ischemic heart disease is a common consequence of coronary artery disease (CAD), which is primarily driven by atherosclerosis, a chronic inflammatory ...

Anocca AB has secured the first regulatory authorization in Europe for a CRISPR-Cas gene-edited T-cell receptor T-cell therapy trial, with the phase I/II study now due to start over the next three ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...

Indian pharma poised to enhance affordability & accessibility of CAR-T cell therapy to combat cancer: Shardul Nautiyal, Mumbai Saturday, April 5, 2025, 08:00 Hrs [IST] The Indian ...

Soligenix is enrolling patients in its FLASH2 study, with a formal interim analysis anticipated early in 2026. <li /> SNGX's HyBryte is a ...

Cellogen Therapeutics’ CAR T cell technology introduces a bi-specific approach to cancer immunotherapy. Unlike conventional CAR T cell therapies that target a single antigen, the company’s platform ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety ...